Menu
Search
|

Menu

Close
X

Teligent Inc TLGT.OQ (NASDAQ Stock Exchange Global Select Market)

4.22 USD
+0.21 (+5.24%)
As of Jul 21
chart
Previous Close 4.01
Open 4.01
Volume 116,296
3m Avg Volume 156,078
Today’s High 4.26
Today’s Low 3.97
52 Week High 8.80
52 Week Low 2.43
Shares Outstanding (mil) 53.39
Market Capitalization (mil) 379.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
15
FY17
67
FY16
67
FY15
44
EPS (USD)
FY18
-0.090
FY17
-0.144
FY16
-0.226
FY15
0.062
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
5.24
5.73
Price to Book (MRQ)
vs sector
6.49
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
198.65
16.84
LT Debt to Equity (MRQ)
vs sector
198.65
12.51
Return on Investment (TTM)
vs sector
-4.71
14.61
Return on Equity (TTM)
vs sector
-13.46
16.34

EXECUTIVE LEADERSHIP

James Gale
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jason Grenfell-Gardner
President, Chief Executive Officer, Director, Since 2012
Salary: $446,250.00
Bonus: $256,148.00
Damian Finio
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Stephen Richardson
Chief Scientific Officer, Since 2015
Salary: $300,000.00
Bonus: $97,800.00
Thomas Sabatino
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

105 Lincoln Avenue
BUENA   NJ   08310

Phone: +1609.6971441

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

SPONSORED STORIES